← Back
Data updated: Mar 10, 2026
HENGRUI PHARMA
OncologyRespiratoryDermatology
HENGRUI PHARMA is a generic drug manufacturer focused on Oncology, Respiratory, Dermatology. Key products include CYCLOPHOSPHAMIDE.
2011
Since
17
Drugs
-
Trials
105
Approved (2yr)
Key Drugs
Recent Activity
DEXMEDETOMIDINE HYDROCHLORIDE 2026-02-17
Labeling
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
OXALIPLATIN 2026-01-15
CISATRACURIUM BESYLATE 2025-11-03
Labeling
OXALIPLATIN 2025-10-22
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 44%
4 drugs Phase 3: 2 Phase 2: 4 Phase 1: 23
Respiratory 23%
1 drugs Phase 3: 2 Phase 2: 5 Phase 1: 9
Dermatology 15%
1 drugs Phase 3: 2 Phase 2: 3 Phase 1: 2
Immunology 10%
0 drugs Phase 2: 5 Phase 1: 4
Infectious Disease 8%
2 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
COSETTE other
Dermatology, Infectious Disease, Immunology, Oncology
Novartis big-pharma
Oncology, Immunology, Respiratory
Active (12)
Discontinued (5)
Company Info
- First Approval
- 2011-12-16
- Latest
- 2025-07-10
- Applications
- 19